These twin innovation cycles of GLP-1 development and digital health innovation for obesity care parallel many dynamics we see in the interplay between medications and digital solutions. As new therapeutics influence the standard of obesity care, we’re tracking the role digital health plays—and what leaders should keep an eye on to maintain a competitive edge as the market evolves.
